NexImmune, Inc. (NASDAQ:NEXI – Get Free Report)’s stock price was down 8.5% on Thursday . The company traded as low as $0.23 and last traded at $0.23. 944 shares were traded during trading, a decline of 100% from the average session volume of 762,352 shares. The stock had previously closed at $0.25.
NexImmune Price Performance
The business’s 50 day simple moving average is $0.27 and its two-hundred day simple moving average is $1.12. The stock has a market capitalization of $319,700.00, a P/E ratio of -0.01 and a beta of 1.68.
NexImmune Company Profile
NexImmune, Inc, a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases in the United States. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform.
See Also
- Five stocks we like better than NexImmune
- NYSE Stocks Give Investors a Variety of Quality Options
- Why Hershey Stock Has More Room to Run Despite Takeover Rejection
- The 3 Best Fintech Stocks to Buy Now
- Texas Instruments: The Old-School Tech Titan Still Delivering
- 5 discounted opportunities for dividend growth investors
- GRAIL: Biotech Stock Targeting $100B Cancer Market
Receive News & Ratings for NexImmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NexImmune and related companies with MarketBeat.com's FREE daily email newsletter.
